Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4538 (nivolumab) plus ipilimumab in advanced melanoma (ONO-4538-17)
jRCT2080222817Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in melanoma, sponsored by Ono Pharmaceutical. Primary endpoint: Objective response rate (central assessment). Started Apr 2015; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on jRCT2080222817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222817.